Adcetris (brentuximab vedotin) / Pfizer, Seagen, Takeda  >>  Phase 2
Welcome,         Profile    Billing    Logout  

71 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adcetris (brentuximab vedotin) / Takeda, Pfizer
ACTRN12619000581167: Brentuximab Vedotin in combination with donor lymphocyte infusions for Hodgkin lymphoma relapsing or persisting after allogeneic stem cell transplantation

Recruiting
2
10
 
Melbourne Health, Millenium Pharmaceuticals
Hodgkin lymphoma
 
 
2018-000873-59: A trial to improve disease control after an allogeneic stem cell transplantation for relapsed or refractory classical Hodgkin lymphoma with consolidation therapy by Brentuximab Vedotin

Not yet recruiting
2
21
Europe
Adcetris, Lyophilisate for solution for infusion, Adcetris
University of Cologne, Takeda Pharmaceutical Company Ltd.
disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV), Diseases [C] - Cancer [C04]
 
 
ACCRU, NCT02758717: Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Checkmark From trial in combination with Opdivo for hodgkin lymphoma at ASH 2019
Dec 2019 - Dec 2019: From trial in combination with Opdivo for hodgkin lymphoma at ASH 2019
Checkmark Presentation of data in combination with Opdivo for 1L Hodgkin lymphoma at ASH 2019
Dec 2019 - Dec 2019: Presentation of data in combination with Opdivo for 1L Hodgkin lymphoma at ASH 2019
Active, not recruiting
2
46
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
08/19
09/24
2019-003084-21: A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgkin lymphoma (cHL) STUDIO ACCADEMICO DI FASE-II TESTANTE, IN DUE COORTI PARALLELE NON RANDOMIZZATE, LA COMBINAZIONE DI RUXOLITINIB (INIBITORE DI JAK 1/2) CON BRENTUXIMAB-VEDOTIN O NIVOLUMAB NEL LINFOMA DI HODGKIN CLASSICO RECIDIVANTE O REFRATTARIO (cHL)

Not yet recruiting
2
27
Europe
Ruxolitinib, brentuximab vedotin, Pembrolizumab, [L01XE18], [L01XC12], [NA], Tablet, Powder for solution for infusion, Concentrate for solution for infusion, JAKAVI - 20 MG - COMPRESSA - USO ORALE - BLISTER (PVC/PCTFE/ALU) - 56 COMPRESSE, ADCETRIS - 50 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO, KEYTRUDA - 50 MG- POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO) 1 FLACONCINO
PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA, Fondi del Dipartimento Medicina
Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment Pazienti con Linfoma di Hodgkin (cHL) recidivato o refrattario che non abbiano risposto o siano andati in progressione dopo il precedente trattamento, Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment Pazienti con Linfoma di Hodgkin (cHL) recidivato o refrattario che non abbiano risposto o siano andati in progressione dopo il precedente trattamento, Diseases [C] - Cancer [C04]
 
 
BV-ALLO, NCT03540849 / 2017-002444-32: BV After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
2
58
Europe
Brentuximab Vedotin (Bv)
University Hospital, Caen
Hodgkin Lymphoma
03/20
03/23
2019-002746-21: A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with ESHAP vsRandomized study to evaluate the efficacy of therapy with BrentuximabVedotin-Etoposide, Methylprednisolone, Cisplatin and Cytarabine (ESHAP)vs ESHAP in patients with Hodgkin's Lymphoma, followed by treatmentwith Brentuximab Vedotin in patients who reach metabolic response aftersalvage therapy Estudio aleatorizado para evaluar la eficacia de la terapia con Brentuximab Vedotin -Etopsido, Metilprednisolona, Cisplatino y Citarabina (ESHAP) vs ESHAP en pacientes con Linfoma de Hodgkin, seguido de tratamiento con Brentuximab Vedotin en pacientes que alcancen respuesta metablica tras la terapia de rescate

Ongoing
2
150
Europe, RoW
Powder for solution for infusion, Adcetris
Fundación GELTAMO, Grupo Español de linfomas y trasplante autologo de medula osea (GELTAMO), Takeda Pharmaceuticals
Patients with Relapsed /Refractory Classical Hodgkin's Lymphoma Pacientes con Linfoma de Hodgkin Clásico Refractario o en Recaída, Hodgkin’s Lymphoma Linfoma de Hodgkin, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01920932: Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Active, not recruiting
2
77
US
brentuximab vedotin, SGN-35, Adcetris(R), etoposide, VP-16, Vepesid(R), prednisone, prednisolone, doxorubicin, Adriamycin(R), cyclophosphamide, Cytoxan(R), Dacarbazine(R), Dimethyl Triazeno Imidazole Carboximide (DTIC), filgrastim, Neupogen(R), quality of life assessment, radiation therapy, irradiation, radiotherapy, radiation
St. Jude Children's Research Hospital, Seagen Inc.
Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
11/20
05/28
2019-003983-28: A phase 2 study of retreatment with brentuximab vedotin in subjects with classic Hodgkin lymphoma or CD30-expressing peripheral T cell lymphoma Studio di fase 2 di ritrattamento con brentuximab vedotin in soggetti affetti da linfoma di Hodgkin classico o linfoma periferico a cellule T CD30-positivo

Not yet recruiting
2
80
Europe
Brentuximab vedotin, [SGN-35], Powder for concentrate for solution for infusion, ADCETRIS®
SEAGEN INC., Seattle Genetics, Inc.
- classic Hodgkin lymphoma (cHL)- Systemic anaplastic large cell lymphoma (sALCL)- CD30-expressing peripheral T cell lymphoma (PTCL) - linfoma di Hodgkin classico (cHL)- Linfoma anaplastico sistemico a grandi cellule (sALCL)- Linfoma a cellule T periferiche che esprimono CD30 (PTCL), - Hodgkin lymphoma- Lymphoma- T cell lymphoma - Linfoma di Hodgkin- Linfoma- Linfoma a cellule T, Diseases [C] - Cancer [C04]
 
 
NCT03057795: Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Active, not recruiting
2
62
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
City of Hope Medical Center, National Cancer Institute (NCI)
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
01/21
12/24
NCT02744612: Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
2
39
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
03/21
12/24
NCT01979536: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Completed
2
137
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039
National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
03/21
03/24
P30CA033572, NCT03113500: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Active, not recruiting
2
48
Canada, US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Etoposide Phosphate, Etopophos, Laboratory Biomarker Analysis, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
City of Hope Medical Center, National Cancer Institute (NCI)
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma, Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
07/21
12/24
2021-003526-80: The standard of care for patients with newly diagnosed CD30-positive PTCL is treatment with a combination of drugs called CHOP. This study is conducted to improve the effectiveness of CHOP chemotherapy with combination therapy, in which vincristine is replaced by brentuximab vedotin. Also, the addition of etoposide to various chemotherapy regimens for T-lymphomas has been associated with promising results in several other studies. This combination is called A + CHEP. Standardem péče pro pacienty s nově zjištěným CD30 pozitivním PTCL je léčba kombinací léků zvaných CHOP. Tato studie se provádí s cílem zlepšit účinnost chemoterapie CHOP s kombinovanou léčbou, v níž se vinkristin nahradí přípravkem brentuximab vedotin. Taktéž přidání etoposidu do různých režimů chemoterapie u T-lymfomů bylo v několika dalších studiích spojeno se slibnými výsledky. Tato kombinace se nazývá A+CHEP [brentuximab vedotin plus cyklofosfamid, doxorubicin, etoposid, prednison].

Not yet recruiting
2
33
RoW
Adcetris, Endoxan, Doxorubicin, Etoposide, Prednison, Kód SÚKL 0193650, Powder for concentrate for solution for infusion, Powder for infusion, Concentrate for solution for infusion, , Tablet, Adcetris, Endoxan, Etoposide, Prednison
Kooperativní lymfomová skupina, z.s., Kooperativní lymfomová skupina, z.s.
Peripheral T-cell lymphomas (PTCL) Periferní T-lymfomy, Agressive lymph node cancer of T-cell origin Agresivní nádorové onemocnění z mízních uzlin z T-buněk, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
AMC-085, NCT02298257: A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma

Completed
2
9
Europe
brentuximab vedotin, adcetris, SGN-35, anti-CD30 ADC SGN-35, anti-CD30 antibody-drug conjugate SGN-35, antibody-drug conjugate SGN-35, Doxorubicin Hydrochloride, Vinblastine, Velban, Velsar, VLB, Dacarbazine
The Lymphoma Academic Research Organisation
HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
12/21
08/22
BVB, NCT02191930 / 2013-003990-89: Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Completed
2
70
Europe
B-CAP, Brentuximab Vedotin, Cyclophosphamide, Doxorubicine, Predniso(lo)ne
University of Cologne
Hodgkin Lymphoma
03/22
03/22
NCT02398240: Brentuximab for Newly Diagnosed Hodgkin Disease

Completed
2
40
US
Brentuximab Vedotin, Adcetris, Doxorubicin, Doxil, Adriamycin, Vincristine, Oncovin, Rituximab, Rituxan
Mitchell Cairo
Hodgkin Lymphoma
06/22
12/22
ACCRU-LY-1601, NCT03233347: Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Active, not recruiting
2
82
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Vinblastine, Vincaleucoblastine, VLB
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
07/22
07/25
NCT03652441: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
21
Europe
Brentuximab Vedotin, BV
University of Cologne
Classical Hodgkin Lymphoma
08/22
08/23
NCT06201507: BV-AVD-R Treatment Children Hodgkin's Lymphoma

Enrolling by invitation
2
44
RoW
Brentuximab vedotin, Adcetris, Rituximab, Rituxan, Doxorubicin, Doxil, Adriamycin, Vincristine, Oncovin, Dacarbazine, DTIC
Beijing Children's Hospital
Hodgkin Lymphoma
12/24
12/25
SGN35-027, NCT03646123 / 2020-004027-17: Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Checkmark Part B and Part C data from SGN35-027 study in combination with Opdivo for classical Hodgkin Lymphoma at ASH 2022
Dec 2022 - Dec 2022: Part B and Part C data from SGN35-027 study in combination with Opdivo for classical Hodgkin Lymphoma at ASH 2022
Terminated
2
255
Europe, US, RoW
brentuximab vedotin, Adcetris, SGN-35, doxorubicin, vinblastine, dacarbazine, G-CSF, filgrastim, pegfilgrastim, nivolumab, Opdivo
Seagen Inc., Bristol-Myers Squibb
Hodgkin Lymphoma
11/22
08/24
2021-005950-27: Imaging study with brentuximab in patients with lymphoma Beeldvormend onderzoek met brentuximab bij patiënten met lymfeklierkanker

Not yet recruiting
2
20
Europe
[89Zr] - Brentuximab, Solution for injection
University Medical Center Groningen, Takeda Pharmaceutical Company Ltd
All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including:Hodgkin lymphoma, T-cell lymphoma, Cutaneous T-cell lymphoma, DLBCL Alle patiënten met histologisch bewezen CD30-positieve (d.w.z. > 1% cellen) lymfomen die zullen worden behandeld met brentuximab vedotin, waaronder: Hodgkin-lymfoom, T-cellymfoom, Cutaan T-cellymfoom, DLBC, Patients with Lymphoma Patiënten met lymfeklierkanker:, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
 
 
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark ASH 2013
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
NCT03198689: Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis

Completed
2
11
Canada
Brentuximab Vedotin, ADCETRIS, SGN-35
Lawson Health Research Institute, Seagen Inc.
Diffuse Cutaneous Systemic Sclerosis
06/23
08/23
COBRA, NCT03517137 / 2017-000498-35: Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Active, not recruiting
2
150
Europe
Brentuximab Vedotin, Adriamycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Radiation Therapy
European Organisation for Research and Treatment of Cancer - EORTC
Advanced Hodgkin Lymphoma
08/23
11/26
BASALT, NCT03474133: Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma

Hourglass Jul 2019 - Dec 2019 : From P2 BASALT trial for r/r classical Hodgkin’s lymphoma
Recruiting
2
80
RoW
Brentuximab Vedotin, Adcetris
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hodgkin's Lymphoma
10/23
12/23
NCT04587687: Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recruiting
2
23
US
Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35
Joseph Tuscano, National Cancer Institute (NCI), Seagen Inc.
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
05/25
LCCC1637, NCT03264131: BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Active, not recruiting
2
16
US
Brentuximab Vedotin, CHEP
UNC Lineberger Comprehensive Cancer Center, Seagen Inc.
Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases
12/23
12/28
NCT03712202: Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Active, not recruiting
2
155
US
Bleomycin, BLEO, BLM, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Vinblastine, Vincaleucoblastine, VLB
City of Hope Medical Center, National Cancer Institute (NCI)
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
12/24
12/24
NCT02588651: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Active, not recruiting
2
23
US
Brentuximab vedotin
Deepa Jagadeesh
T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepato-splenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Enteropathy Associated T-cell Lymphoma, NK T-cell Lymphoma
12/24
12/27
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen Inc.
Peripheral T-cell Lymphoma
05/24
12/25
CheckMate 744, NCT02927769 / 2016-002347-41: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Hourglass Feb 2021 - Dec 2021 : From CheckMate 744 trial for r/r classic hodgkin lymphoma
Checkmark FRom CheckMate 744 trial at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: FRom CheckMate 744 trial at ASH 2018 [screenshot]
Completed
2
72
Europe, Canada, US, RoW
Nivolumab, BMS-936558, Opdivo, brentuximab vedotin, bendamustine
Bristol-Myers Squibb, Seagen Inc.
Hodgkin Disease
05/24
05/24
EATL-001, NCT03217643 / 2016-002782-57: CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.

Completed
2
14
Europe
Brentuximab Vedotin
Imagine Institute, Takeda
Enteropathy Associated T-cell Lymphoma
11/22
05/23
NCT05243693: Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

Recruiting
2
30
RoW
Brentuximab vedotin, Adcetris
National Cancer Center, Korea
Relapsed/Refractory Classical Hodgkin Lymphoma
02/24
03/26
NCT06377566: A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting
2
71
US
Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Pembrolizumab, Gemcitabine, Vinorelbine, FDG-PET/CT scan
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Hodgkin Lymphoma
04/27
04/27
NCT03007030: Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Recruiting
2
55
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
05/25
05/25
OSU-17204, NCT03409432: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Active, not recruiting
2
26
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
John Reneau
Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
05/25
05/25
BV mini CHP, NCT02734771: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting
2
24
US
Brentuximab vedotin, Adcetris, SGN-35, cAC10-vcMMAE, Rituximab, Rituxan, Mabthera, Cyclophosphamide, Cytoxan, Lyophilizedcytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin, Doxorubicin, Adriamycin, Doxil, Caelyx, Myocet, Prednisone, Deltasone, Orasone, Adasone, Deltacortisone, Prednisonum
Patrick Reagan, Seagen Inc.
Diffuse Large B-Cell Lymphoma
06/25
06/25
NCT05316246: Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

Not yet recruiting
2
40
NA
Brentuximab Vedotin in Combination with Tislelizumab
Shanghai Zhongshan Hospital, Takeda, BeiGene
NK/T Cell Lymphoma Nos
06/24
12/24
NCT06393361: Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

Recruiting
2
100
RoW
Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin, anti-PD-1 antibody.
Chinese PLA General Hospital
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
06/26
06/27
NCI-2022-03831, NCT05357794: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Recruiting
2
30
US
Brentuximab vedotin, SGN-35, Adcetris
M.D. Anderson Cancer Center, Seagen Inc.
Mycosis Fungoides
01/26
01/26
NCT05180097: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
84
Canada, RoW
Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab
Canadian Cancer Trials Group, Merck Sharp & Dohme LLC, Seagen Inc., Australasian Leukaemia and Lymphoma Group
Hodgkin Lymphoma
06/25
06/26
RG1713010, NCT01703949: Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Recruiting
2
40
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, CMAB819, Nivolumab Biosimilar CMAB819
University of Washington
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
03/25
03/26
NCT06563778: Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

Not yet recruiting
2
100
RoW
Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody
Chinese PLA General Hospital
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
09/26
09/28
PTCL-CHEPA, NCT05006664: Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Not yet recruiting
2
33
RoW
Adcetris 50 MG Injection, Brentuximab Vedotin, Endoxan, Cyclophosphamide, Doxorubicin, Doxorubicin Ebewe, Doxorubicin Medac, Etoposide, Etoposide ACCORD, Prednisone tablet, Prednison Léčiva
Czech Lymphoma Study Group
Lymphoma, T-Cell, Peripheral
10/24
10/24
NCT04561206: Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma

Recruiting
2
31
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
City of Hope Medical Center, National Cancer Institute (NCI)
Relapsed Classic Hodgkin Lymphoma
10/26
10/26
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/25
07/25
NCT05673785: A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Recruiting
2
52
RoW
Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Takeda
Lymphoma
07/25
12/27
PACIFIC, NCT04745949: Primary Mediastinal Large B-cell Lymphoma Treated with Antibody Therapy, Checkpoint Inhibitor in Frontline with ImmunoChemotherapy

Recruiting
2
31
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
08/25
08/25
NCT01508312: Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
2
46
US
brentuximab vedotin (SGN-35), Brentuximab Vedotin (SGN-35)
Memorial Sloan Kettering Cancer Center, Seagen Inc., Hôpitaux Universitaires Henri Mondor, France
Hodgkin's Lymphoma
03/24
03/24
NCT05922904: PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Recruiting
2
50
US
Brentuximab vedotin, Doxorubicin Hydrochloride, Adriamycin PFS®, Adriamycin RDF™, Adriamycin®, Rubex®, Pembrolizumab, SGN-35, Adcetris, Dacarbazine, DTIC-Dome®
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC, Seagen Inc.
Hodgkin Lymphoma
10/25
10/25
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Recruiting
2
140
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
10/25
09/26
NCT05149768: Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

Recruiting
2
11
Canada
Brentuximab vedotin, ADCETRIS, SGN-35
Lawson Health Research Institute, Seagen Inc.
Diffuse Cutaneous Systemic Sclerosis
02/26
07/26
NCT01352520: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Checkmark In CD30+ MF/SS and LPD and in MF/SS with various degree of CD30 expression
Oct 2015 - Oct 2015: In CD30+ MF/SS and LPD and in MF/SS with various degree of CD30 expression
Checkmark P2 data-ASH
Nov 2012 - Nov 2012: P2 data-ASH
Checkmark P2 data (CTCL)
More
Active, not recruiting
2
79
US
SGN-35, Brentuximab vedotin
M.D. Anderson Cancer Center, Seagen Inc.
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides, Skin Lymphoma, Cutaneous Lymphomas, Lymphoma, Hematologic Disorder
01/26
01/26
NCT04795869: Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Withdrawn
2
40
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Seagen Inc.
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
03/26
03/29
BRESELIBET, NCT04378647: BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Recruiting
2
150
Europe
Induction with Brentuximab vedotin (BV), Adcetris treatment + ESHAP as salvage therapy, Induction without Brentuximab Vedotin, ESHAP treatment as salvage therapy, Consolidation with Brentuximab Vedotin, Adcetris treatment as consolidation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Hodgkin Lymphoma, Adult
08/26
08/26
NCT05039073: Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Recruiting
2
46
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, stem cell transplantation, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, National Cancer Institute (NCI)
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
11/26
11/27
NCT03755804: Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Recruiting
2
250
US
bendamustine, TREANDA (R), Etoposide, VP-16, Vepeside, Doxorubicin, Adriamycin (R), Bleomycin, Blenoxane (R), Vincristine, Oncovin (R), Vinblastine, Velban (R), Prednisone, Prednisolone, Filgrastim, Neupogen (R), Brentuximab Vedotin, Adcetris, Cyclophosphamide, Cytoxan (R), DTIC, DACARBAZINE (R), Dimethyl Triazeno Imidazole Carboximide, Quality of Life Measurements, Quality of Life Measurements (QOL), Radiotherapy, radiation therapy, irradiation
St. Jude Children's Research Hospital, Teva Pharmaceuticals USA, Seagen Inc.
Hodgkin Lymphoma
01/27
07/28
NCT05404945: Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Recruiting
2
44
US
Pembrolizumab, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine, Brentuximab vedotin
University of Virginia, Merck Sharp & Dohme LLC
Classical Hodgkin Lymphoma
10/27
10/27
RADICAL, NCT05253495: Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Recruiting
2
80
US
DOC Group B, Reduction Phase, Pv-COMRAD 1 and 2 Group B, Induction 1 and 2, Pv-R-CYM 1 and 2 Group B, Consolidation 1 and 2, DOC Group C, Reduction with IT, MAD CPR 1 and 2, Induction 1 and 2 Group C, Pv-R CYVE 1 and 2, Consolidation 1 and 2 Group C CNS Negative, Pv-R CYVE-MTX 1 and 2, Consolidation 1 and 2 Group C CNS Positive, MAD CP, Maintenance 1 Group C, Pv-Cytarabine/etoposide, Maintenance 2, 4 Group C, AD CP, Maintenance 3 Group C, Bv-AVD-R 1 and 2: COHORT IIa, Intermediate Risk cohort IIa, Bv-NVD-R, Cycle 1-2, Cohort IIa Rapid Early Responders, Bv-NVD-R, Cycle 1-4 SER, Cohort IIa Slow Early Responders, Bv-AVD-R, High-Risk cohort IIb, Bv-NVD-R, Cycle 1-4 RER, cohort IIb Rapid Early Responders, Bv-NAVD-R, Cycle 1-2, cohort IIb Slow Early Responders, Involved Site Radiation Therapy, Cohort II ONLY
New York Medical College
Non-hodgkin Lymphoma, Hodgkin Lymphoma
12/27
06/28
NCT05313243: Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Recruiting
2
43
US
Brentuximab vedotin, Adcetris, Pembrolizumab, Keytruda
Yale University, Merck Sharp & Dohme LLC
T-Cell Lymphoma
04/28
07/28
jRCT2080221610: A Phase 1/2, Single-arm, Open-label Study of SGN-35 in Japanese Patients with relapsed/refractory CD30-positive Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Completed
1/2
17
Japan
Adcetris (brentuximab vedotin) - Takeda, Pfizer
Takeda Pharmaceutical Company Limited
relapsed/refractory CD30-positive HL or sALCL
 
 
NCT02227199: Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
1/2
45
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis
University of Washington, National Cancer Institute (NCI), Seagen Inc.
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
03/20
09/25
C25004, NCT02979522 / 2015-004112-38: A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Hourglass Apr 2022 - Mar 2023 : Regulatory approval in Japan for pediatric front-line Hodgkin lymphoma
Active, not recruiting
1/2
59
Europe, Japan, US, RoW
Brentuximab vedotin, Adcetris, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine
Takeda
Hodgkin Disease
05/20
09/29
NCT01771107: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Active, not recruiting
1/2
41
Europe, US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Pharmacological Study, Vinblastine, Vincaleucoblastine, VLB
National Cancer Institute (NCI), The Lymphoma Academic Research Organisation
AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, HIV Infection
10/21
02/25
NCT02098512: Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Active, not recruiting
1/2
20
US
Brentuximab Vedotin, Adcetris, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning
New York Medical College, St. Baldrick's Foundation
Hodgkin Lymphoma
12/21
12/22
HOVON 136 NHL, NCT03356054 / 2016-001211-21: Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Recruiting
1/2
37
Europe
R-DHAP, Brentuximab Vedotin, Adcetris
Stichting Hemato-Oncologie voor Volwassenen Nederland
DLBCL
01/23
02/27
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
NCT03187210: Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

Suspended
1/2
20
Europe
Brentuximab Vedotin, BeEAM Regimen
Insel Gruppe AG, University Hospital Bern, Mundipharma Medical Company
Lymphoma
11/23
11/24
NCT03246750: B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma

Completed
1/2
34
RoW
B-MAD chemotherapy, Involved field radation, cisplatin
The Thai Lymphoma Study Group, Takeda
Extranodal NK/T-cell Lymphoma
04/24
04/24
NCT03576378 / 2017-003689-28: BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
41
Europe
BrentuximabVedotin (BV), cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Takeda
Hodgkin Lymphoma
10/23
10/24
E4412, NCT01896999: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Checkmark Results in combination with Opdivo & Adcentris
Dec 2018 - Dec 2018: Results in combination with Opdivo & Adcentris
Active, not recruiting
1/2
146
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
03/25
03/25

Download Options